Generic schizophrenia drug shows promise in early test

NCT ID NCT07266792

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a generic version of the schizophrenia drug brexpiprazole works the same as the brand-name drug (Rxulti). Thirty-six healthy adults took a single dose of each version, and researchers measured drug levels in their blood. The goal was to see if the generic is absorbed similarly, which could lead to a more affordable treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Brexpiprazole

What this could lead to

If successful, this could show that the generic version of brexpiprazole is equivalent to the brand-name drug, potentially offering a lower-cost option for schizophrenia treatment.

What could go wrong

This was a small, early-phase study in healthy people, not patients. It only measured drug levels in the blood, not actual treatment effects or safety in schizophrenia.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cliantha Research Limited

    Ahmedabad, Gujarat, 382210, India